Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atrasentan Extension in Hormone-Refractory Prostate Cancer
NCT00046943Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Sep 2002
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of atrasentan in prostate cancer (PCa), sponsored by Abbott Laboratories. Primary endpoint: Safety of atrasentan at 3 years. Started Sep 2002; status: completed.
02
Drugs
atrasentan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00046943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00046943.